4D Molecular Therapeutics, Inc. Research and Development Expense (Excluding Acquired in Process Cost)
4D Molecular Therapeutics, Inc. (FDMT) reported Research and Development Expense (Excluding Acquired in Process Cost) of $68.28 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. research and development expense (excluding acquired in process cost) for the quarter ending 2026-06-30 was $68.28M, a 42.40% increase year-over-year.
- 4D Molecular Therapeutics, Inc. research and development expense (excluding acquired in process cost) for the quarter ending 2026-03-31 was $64.98M, a 59.66% increase year-over-year.
- 4D Molecular Therapeutics, Inc. research and development expense (excluding acquired in process cost) for the quarter ending 2025-12-31 was $57.61M, a 33.70% increase year-over-year.
- 4D Molecular Therapeutics, Inc. research and development expense (excluding acquired in process cost) for the quarter ending 2025-09-30 was $49.44M, a 28.46% increase year-over-year.
- 4D Molecular Therapeutics, Inc. research and development expense (excluding acquired in process cost) for fiscal 2025 was $195.70M, a 38.50% increase from fiscal 2024.
- 4D Molecular Therapeutics, Inc. research and development expense (excluding acquired in process cost) for fiscal 2024 was $141.30M, a 45.53% increase from fiscal 2023.
- 4D Molecular Therapeutics, Inc. research and development expense (excluding acquired in process cost) for fiscal 2023 was $97.10M, a 20.99% increase from fiscal 2022.
- 4D Molecular Therapeutics, Inc. research and development expense (excluding acquired in process cost) for fiscal 2022 was $80.25M, a 30.79% increase from fiscal 2021.
| Period end | Research and Development Expense (Excluding Acquired in Process Cost) 3 month | Research and Development Expense (Excluding Acquired in Process Cost) 6 month | Research and Development Expense (Excluding Acquired in Process Cost) 9 month | Research and Development Expense (Excluding Acquired in Process Cost) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $68.28M 10-Q · filed 2026-08-13 | $133.26M 10-Q · filed 2026-08-13 | $190.87M derived: sum of 3 quarters · filed 2026-08-13 | $240.31M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $64.98M 10-Q · filed 2026-05-07 | $122.59M derived: sum of 2 quarters · filed 2026-05-07 | $172.03M derived: sum of 3 quarters · filed 2026-05-07 | $219.98M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $57.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $107.05M derived: sum of 2 quarters · filed 2026-03-18 | $155.00M derived: sum of 3 quarters · filed 2026-08-13 | $195.70M 10-K · filed 2026-03-18 |
| 2025-09-30 | $49.44M 10-Q · filed 2025-11-10 | $97.39M derived: sum of 2 quarters · filed 2026-08-13 | $138.09M 10-Q · filed 2025-11-10 | $181.18M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $47.95M 10-Q · filed 2026-08-13 | $88.65M 10-Q · filed 2026-08-13 | $131.74M derived: sum of 3 quarters · filed 2026-08-13 | $170.22M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $40.70M 10-Q · filed 2026-05-07 | $83.79M derived: sum of 2 quarters · filed 2026-05-07 | $122.27M derived: sum of 3 quarters · filed 2026-05-07 | $154.13M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $43.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $81.57M derived: sum of 2 quarters · filed 2026-03-18 | $113.43M derived: sum of 3 quarters · filed 2026-03-18 | $141.30M 10-K · filed 2026-03-18 |
| 2024-09-30 | $38.48M 10-Q · filed 2025-11-10 | $70.34M derived: sum of 2 quarters · filed 2025-11-10 | $98.21M 10-Q · filed 2025-11-10 | $124.24M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $31.86M 10-Q · filed 2025-08-11 | $59.73M 10-Q · filed 2025-08-11 | $85.76M derived: sum of 3 quarters · filed 2025-08-11 | $110.82M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $27.87M 10-Q · filed 2025-05-08 | $53.90M derived: sum of 2 quarters · filed 2025-05-08 | $78.96M derived: sum of 3 quarters · filed 2025-05-08 | $102.55M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $26.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $51.09M derived: sum of 2 quarters · filed 2025-02-28 | $74.68M derived: sum of 3 quarters · filed 2025-02-28 | $97.10M 10-K · filed 2025-02-28 |
| 2023-09-30 | $25.07M 10-Q · filed 2024-11-13 | $48.65M derived: sum of 2 quarters · filed 2024-11-13 | $71.07M 10-Q · filed 2024-11-13 | $92.56M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $23.58M 10-Q · filed 2024-08-08 | $46.00M 10-Q · filed 2024-08-08 | $67.50M derived: sum of 3 quarters · filed 2024-08-08 | $86.44M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $22.41M 10-Q · filed 2024-05-09 | $43.91M derived: sum of 2 quarters · filed 2024-05-09 | $62.85M derived: sum of 3 quarters · filed 2024-05-09 | $83.27M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $21.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $40.44M derived: sum of 2 quarters · filed 2024-02-29 | $60.86M derived: sum of 3 quarters · filed 2024-02-29 | $80.25M 10-K · filed 2024-02-29 |
| 2022-09-30 | $18.94M 10-Q · filed 2023-11-09 | $39.36M derived: sum of 2 quarters · filed 2023-11-09 | $58.75M 10-Q · filed 2023-11-09 | $76.27M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $20.42M 10-Q · filed 2023-08-09 | $39.82M 10-Q · filed 2023-08-09 | $57.33M derived: sum of 3 quarters · filed 2023-08-09 | $73.17M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $19.38M 10-Q · filed 2023-05-11 | $36.91M derived: sum of 2 quarters · filed 2023-05-11 | $52.75M derived: sum of 3 quarters · filed 2023-05-11 | $67.97M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $17.53M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $33.37M derived: sum of 2 quarters · filed 2023-03-15 | $48.59M derived: sum of 3 quarters · filed 2023-03-15 | $61.36M 10-K · filed 2023-03-15 |
| 2021-09-30 | $15.84M 10-Q · filed 2022-11-08 | $31.06M derived: sum of 2 quarters · filed 2022-11-08 | $43.83M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $15.22M 10-Q · filed 2022-08-11 | $27.99M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $12.77M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | $53.04M 10-K · filed 2022-03-28 | |||
| 2019-12-31 | $38.72M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |